InterventionsHuman trial
SAT-587 The Effects of Dapagliflozin on Diabetes Mellitus without Cardiovascular Disease
ENDO 2025 Abstract
Related
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026